Van Voorhees Seth's Form 4 filing
NRX Pharmaceuticals, Inc. (NRXP) · filed Nov 28, 2022
- Accession no.
- 0001415889-22-011778
- Filed
- Nov 28, 2022
- Trade date
- Nov 25, 2022
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $18.2K. It was filed 3 days after the trade.
This filing was later replaced by the amendment 0001415889-22-012650 (Dec 19, 2022). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Van Voorhees SethCIK 0001284934 | Officer (CHIEF FINANCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 25, 2022 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +8,716 | $1.12 | +$9,761.92 | 8,716 | Indirect | |
| Nov 25, 2022 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +600 | $1.10 | +$660 | 9,316 | Indirect | |
| Nov 25, 2022 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +7,021 | $1.11 | +$7,793.31 | 16,377 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.